In addition, CMTM6 expression was associated with differentiation in lung cancer (Hou et al., 2020), with a better prognosis in OV (Yin et al., 2022), and significantly higher in triple-negative breast cancer (TNBC) than HER2-driven breast cancer (Tian et al., 2021). Here, ERBB2 is linked to triple-negative breast carcinoma.